{"product_id":"chemistry-and-pharmacology-of-drug-discovery","title":"Chemistry and Pharmacology of Drug Discovery","description":"\u003cp\u003e\u003cb\u003eCase studies of 20 successful FDA-approved drugs, from biological rationale to clinical efficacy studies and state-of-the-art applications\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003eChemistry and Pharmacology of Drug Discovery\u003c\/i\u003e illustrates how chemistry, biology, pharmacokinetics, and a host of disciplines come together to produce successful medicines, discussing a total of 20 drugs that are all FDA-approved post 2021—some of which are first-in-class and revolutionary. \u003c\/p\u003e\u003cp\u003eThe four sections in this book cover Infectious Disease, Cancer Drugs, CNS Drugs, and Miscellaneous Drugs. Each chapter covers background material on the drug class and\/or disease indication and key aspects relevant to the discovery of the drug, including structure-activity relationships, pharmacokinetics, drug metabolism, efficacy, and safety. \u003c\/p\u003e\u003cp\u003eThis book is contributed to by various veterans and well-known experts in medical chemistry, many of whom discovered the drugs they reviewed, leading to tremendous quality and depth of insight. \u003c\/p\u003e\u003cp\u003eSome of the drugs covered in \u003ci\u003eChemistry and Pharmacology of Drug Discovery\u003c\/i\u003e include: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eNirmatrelvir (Paxlovid with Ritonavir), a 3-chymotrypsin-like protease inhibitor for treating SARS-CoV-2 infection\u003c\/li\u003e\n\u003cli\u003eDoravirine (Pifeltro), a third-generation non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection\u003c\/li\u003e\n\u003cli\u003eOteseconazole (Vivjoa), a CYP51 inhibitor for treating recurrent vulvovaginal candidiasis, and Rimegepant (Nurtec ODT), a CGRP antagonist for treating migraine\u003c\/li\u003e\n\u003cli\u003eCiprofol (Cipepofol), a γ-Aminobutyric acid receptor agonist for induction of anesthesia, and Ozanimod (Zeposia), an S1P receptor antagonist for treating multiple sclerosis\u003c\/li\u003e\n\u003cli\u003eDeucravacitinib (Sotyktu), a first-in-class deuterated TYK2 inhibitor for the treatment of plaque psoriasis\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003ci\u003eChemistry and Pharmacology of Drug Discovery\u003c\/i\u003e serves as an excellent and highly authoritative learning resource for medicinal, organic, synthetic, and process chemists as well as research scientists in lead optimization and process development.\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":53972226081112,"sku":null,"price":193.44,"currency_code":"EUR","in_stock":false}],"url":"https:\/\/agendabookshop.com\/products\/chemistry-and-pharmacology-of-drug-discovery","provider":"Agenda Bookshop","version":"1.0","type":"link"}